D2M Biotherapeutics, a tumor immunological drug developer, recently completed a Pre-A round of US$10 million in financing led by Apricot Capital (Shanghai).
Immvira officially announced the completion of a 58 million US dollars (400 million yuan) Series B financing round. The round was led by Huagai Capital, with participation from Apricot Capital, Cowin Capital, and GL Ventures, the leading investor in the previous round.
Jiushi Shenkang has raised nearly 100 million yuan in a Series A financing round. This round of financing was led by Apricot Capital. The proceeds will be used to promote the clinical research of new products of its neural intervention product pipeline, and the marketing and industrialization of the subsequent product launching.